​

Bicara Therapeutics Stock (NASDAQ:BCAX)

ForecastOwnershipFinancialsChartTranscripts
Bicara Therapeutics by TradingView

Previous Close

$20.56

52W Range

$8.48 - $24.25

50D Avg

$21.65

200D Avg

$17.53

Market Cap

$1.11B

Avg Vol (3M)

$534.65K

Beta

-0.53

Div Yield

-

BCAX Company Profile

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

Sep 13, 2024

Website

BCAX Performance

BCAX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-82.39M$-39.89M$-37.66M
Net Income$-68.00M$-51.98M$-37.84M
EBITDA$-82.39M$-51.96M$-37.72M
Basic EPS$-0.40$-1.00$-0.73
Diluted EPS$-0.40$-1.00$-0.73

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 30, 26 | 8:30 AM

Peer Comparison

TickerCompany
TNGXTango Therapeutics, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
SEPNSepterna, Inc.
KURAKura Oncology, Inc.
FTREFortrea Holdings Inc.
PRMEPrime Medicine, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
PROKProKidney Corp.
SVRASavara Inc.
PHATPhathom Pharmaceuticals, Inc.